Amicus Therapeutics Inc
(FRA:AM6)
€
9.1
0.05 (0.55%)
Market Cap: 2.62 Bil
Enterprise Value: 2.81 Bil
PE Ratio: 0
PB Ratio: 15.06
GF Score: 73/100 
Amicus Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 12, 2019 / 12:00PM GMT
Release Date Price:
€11.82
(+3.32%)
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
Well, good morning, everyone. It's my distinct pleasure to start us off with the conference here with certainly one of the more uplifting stories, I think, in all of biotech, but joining me today from Amicus Therapeutics is Daphne Quimi and Jeff Castelli. Thank you so much for joining us.
Jeffrey P. Castelli
Amicus Therapeutics, Inc. - Chief Portfolio Officer & Head of Gene Therapy
Thank you.
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
My name is Jason Zemansky. I am an associate on Geoff Meacham's team, large cap biopharma analyst at Barclays.
So I think we should just dive into the questions.
Questions & Answers
Jason Eron Zemansky
Barclays Bank PLC, Research Division - Research Analyst
So certainly, a large milestone in Amicus' story was the commercial approval of Galafold last August. Can you tell us a little bit about the feedback
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers